The Experts below are selected from a list of 28554 Experts worldwide ranked by ideXlab platform
Lisa A. Prosser - One of the best experts on this subject based on the ideXlab platform.
-
Cost-Effectiveness of Oseltamivir Treatment for Children with Uncomplicated Seasonal Influenza
The Journal of pediatrics, 2011Co-Authors: Tara A. Lavelle, Timothy M. Uyeki, Lisa A. ProsserAbstract:Objective To evaluate the cost-effectiveness of oseltamivir treatment for Seasonal Influenza in children and consider the impact of oseltamivir resistance on these findings. Study design We developed a model to evaluate 1-year clinical and economic outcomes associated with 3 outpatient management strategies for unvaccinated children with Influenza-like-illness: no antiviral treatment; diagnostic testing and oseltamivir treatment when positive; and empiric oseltamivir treatment. The model depicted a hypothetical non-pandemic Influenza season with a 29% level of oseltamivir resistance in circulating viruses, and 14% to 54% probability of Seasonal Influenza with Influenza-like-illness. Strategies were compared with incremental cost-effectiveness ratios. Results In our primary analysis, empiric oseltamivir treatment consistently produced the greatest benefit. The incremental cost-effectiveness of this alternative, compared with testing and treating, was Conclusion Empiric oseltamivir treatment of Seasonal Influenza is associated with favorable cost-effectiveness ratios, particularly in children aged 1 to
Anthony S Fauci - One of the best experts on this subject based on the ideXlab platform.
-
chasing Seasonal Influenza the need for a universal Influenza vaccine
The New England Journal of Medicine, 2018Co-Authors: Catharine I Paules, Sheena G. Sullivan, Kanta Subbarao, Anthony S FauciAbstract:Chasing Seasonal Influenza As we prepare for a potentially severe Influenza season, we must consider whether our current vaccines can be improved and whether longer-term, transformative vaccine approaches are needed to minimize Influenza-related morbidity and mortality.
-
Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine
The New England Journal of Medicine, 2017Co-Authors: Catharine I Paules, Sheena G. Sullivan, Kanta Subbarao, Anthony S FauciAbstract:Chasing Seasonal Influenza As we prepare for a potentially severe Influenza season, we must consider whether our current vaccines can be improved and whether longer-term, transformative vaccine approaches are needed to minimize Influenza-related morbidity and mortality.
Philippe Buchy - One of the best experts on this subject based on the ideXlab platform.
-
Seasonal Influenza vaccination in patients with COPD: a systematic literature review
BMC pulmonary medicine, 2017Co-Authors: Rafik Bekkat-berkani, Philippe Buchy, Tom Wilkinson, Gael Dos Santos, Dimitris Stefanidis, Jeanne-marie Devaster, Nadia MeyerAbstract:Influenza is a frequent cause of exacerbations of chronic obstructive pulmonary disease (COPD). Exacerbations are associated with worsening of the airflow obstruction, hospitalisation, reduced quality of life, disease progression, death, and ultimately, substantial healthcare-related costs. Despite longstanding recommendations to vaccinate vulnerable high-risk groups against Seasonal Influenza, including patients with COPD, vaccination rates remain sub-optimal in this population. We conducted a systematic review to summarise current evidence from randomised controlled trials (RCTs) and observational studies on the immunogenicity, safety, efficacy, and effectiveness of Seasonal Influenza vaccination in patients with COPD. The selection of relevant articles was based on a three-step selection procedure according to predefined inclusion and exclusion criteria. The search yielded 650 unique hits of which 48 eligible articles were screened in full-text. Seventeen articles describing 13 different studies were found to be pertinent to this review. Results of four RCTs and one observational study demonstrate that Seasonal Influenza vaccination is immunogenic in patients with COPD. Two studies assessed the occurrence of COPD exacerbations 14 days after Influenza vaccination and found no evidence of an increased risk of exacerbation. Three RCTs showed no significant difference in the occurrence of systemic effects between groups receiving Influenza vaccine or placebo. Six out of seven studies on vaccine efficacy or effectiveness indicated long-term benefits of Seasonal Influenza vaccination, such as reduced number of exacerbations, reduced hospitalisations and outpatient visits, and decreased all-cause and respiratory mortality. Additional large and well-designed observational studies would contribute to understanding the impact of disease severity and patient characteristics on the response to Influenza vaccination. Overall, the evidence supports a positive benefit-risk ratio for Seasonal Influenza vaccination in patients with COPD, and supports current vaccination recommendations in this population.
-
Seasonal Influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region.
Western Pacific surveillance and response journal : WPSAR, 2013Co-Authors: Dominic E. Dwyer, Sheena G. Sullivan, Philippe Buchy, Ian G. Barr, Aeron C. Hurt, Anne Kelso, Patrick C. Reading, Jiandong Zheng, Yuelong ShuAbstract:Objective: Vaccination is the most effective way to prevent Seasonal Influenza and its severe outcomes. The objective of our study was to synthesize information on Seasonal Influenza vaccination policies, recommendations and practices in place in 2011 for all countries and areas in the Western Pacific Region of the World Health Organization (WHO). Methods: Data were collected via a questionnaire on Seasonal Influenza vaccination policies, recommendations and practices in place in 2011. Results: Thirty-six of the 37 countries and areas (97%) responded to the survey. Eighteen (50%) reported having established Seasonal Influenza vaccination policies, an additional seven (19%) reported having recommendations for risk groups for Seasonal Influenza vaccination only and 11 (30%) reported having no policies or recommendations in place. Of the 25 countries and areas with policies or recommendations, health-care workers and the elderly were most frequently recommended for vaccination; 24 (96%) countries and areas recommended vaccinating these groups, followed by pregnant women (19 [76%]), people with chronic illness (18 [72%]) and children (15 [60%]). Twenty-six (72%) countries and areas reported having Seasonal Influenza vaccines available through public funding, private market purchase or both. Most of these countries and areas purchased only enough vaccine to cover 25% or less of their populations. Discussion: In light of the new WHO position paper on Influenza vaccines published in 2012 and the increasing availability of country-specific data, countries and areas should consider reviewing or developing their Seasonal Influenza vaccination policies to reduce morbidity and mortality associated with annual epidemics and as part of ongoing efforts for pandemic preparedness.
-
Heterosubtypic antibody response elicited with Seasonal Influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
PLoS ONE, 2011Co-Authors: Heng Ding, Cheguo Tsai, Fan Zhou, Philippe Buchy, Vincent Deubel, Paul ZhouAbstract:BACKGROUND: The spread of highly pathogenic avian Influenza (HPAI) H5N1 virus in human remains a global health concern. Heterosubtypic antibody response between Seasonal Influenza vaccine and potential pandemic Influenza virus has important implications for public health. Previous studies by Corti et al. and by Gioia et al. demonstrate that heterosubtypic neutralizing antibodies against the highly pathogenic H5N1 virus can be elicited with a Seasonal Influenza vaccine in humans. However, whether such response offers immune protection against highly pathogenic H5N1 virus remained to be determined. METHODOLOGY/PRINCIPAL FINDINGS: In this study, using a sensitive Influenza HA (hemagglutinin) and NA (neuraminidase) pseudotype-based neutralization (PN) assay we first confirmed that low levels of heterosubtypic neutralizing antibody response against H5N1 virus were indeed elicited with Seasonal Influenza vaccine in humans. We then immunized mice with the Seasonal Influenza vaccine and challenged them with lethal doses of highly pathogenic H5N1 virus. As controls, we immunized mice with homosubtypic H5N1 virus like particles (VLP) or PBS and challenged them with the same H5N1 virus. Here we show that low levels of heterosubtypic neutralizing antibody response were elicited with Seasonal Influenza vaccine in mice, which were significantly higher than those in PBS control. Among them 2 out of 27 whose immune sera exhibited similar levels of neutralizing antibody response as VLP controls actually survived from highly pathogenic H5N1 virus challenge. CONCLUSIONS/SIGNIFICANCE: Therefore, we conclude that low levels of heterosubtypic neutralizing antibody response are indeed elicited with Seasonal Influenza vaccine in humans and mice and at certain levels such response offers immune protection against severity of H5N1 virus infection.
Sheena G. Sullivan - One of the best experts on this subject based on the ideXlab platform.
-
chasing Seasonal Influenza the need for a universal Influenza vaccine
The New England Journal of Medicine, 2018Co-Authors: Catharine I Paules, Sheena G. Sullivan, Kanta Subbarao, Anthony S FauciAbstract:Chasing Seasonal Influenza As we prepare for a potentially severe Influenza season, we must consider whether our current vaccines can be improved and whether longer-term, transformative vaccine approaches are needed to minimize Influenza-related morbidity and mortality.
-
Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine
The New England Journal of Medicine, 2017Co-Authors: Catharine I Paules, Sheena G. Sullivan, Kanta Subbarao, Anthony S FauciAbstract:Chasing Seasonal Influenza As we prepare for a potentially severe Influenza season, we must consider whether our current vaccines can be improved and whether longer-term, transformative vaccine approaches are needed to minimize Influenza-related morbidity and mortality.
-
Seasonal Influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region.
Western Pacific surveillance and response journal : WPSAR, 2013Co-Authors: Dominic E. Dwyer, Sheena G. Sullivan, Philippe Buchy, Ian G. Barr, Aeron C. Hurt, Anne Kelso, Patrick C. Reading, Jiandong Zheng, Yuelong ShuAbstract:Objective: Vaccination is the most effective way to prevent Seasonal Influenza and its severe outcomes. The objective of our study was to synthesize information on Seasonal Influenza vaccination policies, recommendations and practices in place in 2011 for all countries and areas in the Western Pacific Region of the World Health Organization (WHO). Methods: Data were collected via a questionnaire on Seasonal Influenza vaccination policies, recommendations and practices in place in 2011. Results: Thirty-six of the 37 countries and areas (97%) responded to the survey. Eighteen (50%) reported having established Seasonal Influenza vaccination policies, an additional seven (19%) reported having recommendations for risk groups for Seasonal Influenza vaccination only and 11 (30%) reported having no policies or recommendations in place. Of the 25 countries and areas with policies or recommendations, health-care workers and the elderly were most frequently recommended for vaccination; 24 (96%) countries and areas recommended vaccinating these groups, followed by pregnant women (19 [76%]), people with chronic illness (18 [72%]) and children (15 [60%]). Twenty-six (72%) countries and areas reported having Seasonal Influenza vaccines available through public funding, private market purchase or both. Most of these countries and areas purchased only enough vaccine to cover 25% or less of their populations. Discussion: In light of the new WHO position paper on Influenza vaccines published in 2012 and the increasing availability of country-specific data, countries and areas should consider reviewing or developing their Seasonal Influenza vaccination policies to reduce morbidity and mortality associated with annual epidemics and as part of ongoing efforts for pandemic preparedness.
Yuelong Shu - One of the best experts on this subject based on the ideXlab platform.
-
Nonpharmaceutical Interventions Used to Control COVID-19 Reduced Seasonal Influenza Transmission in China.
The Journal of infectious diseases, 2020Co-Authors: Hao Lei, Xiao Wang, Yu Xie, Tao Chen, Lei Yang, Dayan Wang, Yuelong ShuAbstract:To suppress the ongoing COVID-19 pandemic, the Chinese government has implemented nonpharmaceutical interventions (NPIs). Because COVID-19 and Influenza have similar means of transmission, NPIs targeting COVID-19 may also affect Influenza transmission. In this study, the extent to which NPIs targeting COVID-19 have affected Seasonal Influenza transmission was explored. Indicators of Seasonal Influenza activity in the epidemiological year 2019-2020 were compared with those in 2017-2018 and 2018-2019. The incidence rate of Seasonal Influenza reduced by 64% in 2019-2020 (P < .001). These findings suggest that NPIs aimed at controlling COVID-19 significantly reduced Seasonal Influenza transmission in China.
-
Seasonal Influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region.
Western Pacific surveillance and response journal : WPSAR, 2013Co-Authors: Dominic E. Dwyer, Sheena G. Sullivan, Philippe Buchy, Ian G. Barr, Aeron C. Hurt, Anne Kelso, Patrick C. Reading, Jiandong Zheng, Yuelong ShuAbstract:Objective: Vaccination is the most effective way to prevent Seasonal Influenza and its severe outcomes. The objective of our study was to synthesize information on Seasonal Influenza vaccination policies, recommendations and practices in place in 2011 for all countries and areas in the Western Pacific Region of the World Health Organization (WHO). Methods: Data were collected via a questionnaire on Seasonal Influenza vaccination policies, recommendations and practices in place in 2011. Results: Thirty-six of the 37 countries and areas (97%) responded to the survey. Eighteen (50%) reported having established Seasonal Influenza vaccination policies, an additional seven (19%) reported having recommendations for risk groups for Seasonal Influenza vaccination only and 11 (30%) reported having no policies or recommendations in place. Of the 25 countries and areas with policies or recommendations, health-care workers and the elderly were most frequently recommended for vaccination; 24 (96%) countries and areas recommended vaccinating these groups, followed by pregnant women (19 [76%]), people with chronic illness (18 [72%]) and children (15 [60%]). Twenty-six (72%) countries and areas reported having Seasonal Influenza vaccines available through public funding, private market purchase or both. Most of these countries and areas purchased only enough vaccine to cover 25% or less of their populations. Discussion: In light of the new WHO position paper on Influenza vaccines published in 2012 and the increasing availability of country-specific data, countries and areas should consider reviewing or developing their Seasonal Influenza vaccination policies to reduce morbidity and mortality associated with annual epidemics and as part of ongoing efforts for pandemic preparedness.
